[Treatment of the acute coronary syndrome in Germany: experiences in a German cluster of the GRACE registry]
| Autor: | U, Tebbe, P, Bramlage, P, von Löwis of Menar, H, Lawall, P, Gaudron, S, Lüders, A, Klaus, W, Lengfelder, K H, Scholz, S, Maziejewski, A, Cuneo, V, Hohmann, D, Gulba |
|---|---|
| Jazyk: | němčina |
| Rok vydání: | 2007 |
| Předmět: |
Male
Adrenergic Antagonists Cardiotonic Agents Anticholesteremic Agents Myocardial Infarction Anticoagulants Angiotensin-Converting Enzyme Inhibitors Coronary Disease Middle Aged Calcium Channel Blockers Prognosis Germany Acute Disease Cluster Analysis Humans Female Thrombolytic Therapy Angina Unstable Registries Angioplasty Balloon Coronary Coronary Artery Bypass Anti-Arrhythmia Agents Platelet Aggregation Inhibitors Aged |
| Zdroj: | Deutsche medizinische Wochenschrift (1946). 132(39) |
| ISSN: | 1439-4413 |
| Popis: | The acute coronary syndrome (ACS) remains a major cause of mortality and morbidity in the western world. The Global Registry of Acute Coronary Events (GRACE) documents inpatients with all types of ACS and a follow-up at three months in Germany and worldwide.The data of the German Cluster Detmold were compared with data from the worldwide GRACE registry (31,070 patients). Data from 849 patients with ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA) were collected from October 2001 to September 2005 in eight participating hospitals in the GRACE2 Cluster Detmold.Compared with the worldwide GRACE data the patients in the Cluster Detmold had longer pre-hospital admission times (STEMI patients1 h: 13.9 % vs. 17.0 %; p0.05); more frequent interventions (PCI 60.1 % vs. 48.7%; p0.001) and less thrombolysis (17.9 vs. 42.5%; p0.001) in STEMI patients; more frequent use of platelet inhibitors (clopidogrel and ticlopidine, 93.4 % vs. 89.4%; p0.001) and unfractionated heparin (69.8 % vs. 36.5; p0.001), and less frequent use of low molecular weight heparin (31.1 % vs. 51.2%; p0.001); more frequent use of RAS blocking agents (80.2 vs. 66.6, p0.001) and beta blockers (87.4 vs. 78.8, p0.001) and less frequent use of lipid lowering agents (23.5 vs. 72.5%; p0.001).Current management of ACS in Germany closely follows the recommendations of the German society of Cardiology. Differences in practice may account for the observed substantially lower event rates in Germany during hospitalization, but there is still room for improvement in the pre-hospital phase und in the degree to which pharmacotherapy is used for secondary prevention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|